PHAT - Phathom Pharma gains after a series of insider purchases

Shares of Phathom Pharmaceuticals (NASDAQ:PHAT) are trading higher for the third straight session on Tuesday after three top executives of the clinical-stage biopharma company made a series of insider purchases in recent days.   Phathom’s (PHAT) Chief Executive Curran Terrie, Chief Operating Officer Nabulsi Azmi and director Parikh Asit were among those who executed the trades, according to SEC filings submitted on Monday. Notably, CEO Terrie has increased her stake by ~46% on Friday with the purchase of 20,500 Phathom (PHAT) shares at $7.41 apiece in a transaction valued at $151,835. COO Azmi has added 20,000 shares at $8.16 per unit for $163,288 in total to raise the stake by ~3% on Monday, while Asit bought 12,500 Phathom (PHAT) shares for the first time in a transaction valued at ~$100,000. The insider purchases come amid the recent selloff of Phathom (PHAT) shares. The stock has lost more than 70% over the past 12

For further details see:

Phathom Pharma gains after a series of insider purchases